Breaking News Instant updates and real-time market news.

M

Macy's

$21.50

0.21 (0.99%)

11:05
07/05/19
07/05
11:05
07/05/19
11:05

Macy's call volume above normal and directionally bullish

Bullish option flow detected in Macy's with 9,986 calls trading, 2.0x expected, and implied vol increasing almost 2 points to 32.13%. Jul-19 22 calls and 7/12 weekly 21 puts are the most active options, with total volume in those strikes near 3,700 contracts. The Put/Call Ratio is 0.49. Earnings are expected on August 14th.

M Macy's
$21.50

0.21 (0.99%)

05/08/19
CLVD
05/08/19
NO CHANGE
CLVD
Neutral
Macy's Q1 owned comps estimate lowered at Cleveland Research
Cleveland Research analyst Rusty Wilson lowered his Q1 owned comp store sales estimate for Macy's to down 0.5% from flat, citing weather headwinds and soft trends during Easter and the company's "Friends & Family" event. He noted that consensus calls for a 0.1% decline in owned comps in Q1. Wilson, who also thinks gross margin will be pressured by elevated markdowns and promotions in Q1, keeps a Neutral rating on Macy's shares.
05/16/19
GSCO
05/16/19
UPGRADE
Target $21
GSCO
Neutral
Macy's upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Alexandra Walvis upgraded Macy's to Neutral from Sell while lowering her price target for the shares to $21 from $23. Following the company's Q1 results, the analyst sees a more balanced risk/reward in the wake of the stock's recent underperformance. Since her Sell initiation on September 3, 2018, Macy's shares have fallen 41%. While the company continues to face "fading fundamentals" in the medium term as secular challenges weigh, the stock's near term risk/reward is now less skewed to the downside, Walvis tells investors in a research note. Further, she believes Macy's planned quantification of its cost savings program this fall and a potential update on the monetization of Herald Square as potential near-term catalysts for the shares.
05/16/19
MSCO
05/16/19
NO CHANGE
Target $20
MSCO
Underweight
Macy's EPS beat masks 'worrying' core retail performance, says Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said the 11c EPS beat reported by Macy's compared to consensus was driven by lower taxes, real estate gains and credit card revenue growth outperformance. However, she estimates that Macy's had a 0% core retail operating margin in Q1 and noted that its trend of shrinking core retail EBIT dollars, which began in 2015, has continued. The company's same-store comparisons were the easiest of the year in Q1 and Macy's laps significantly more difficult comparisons in the second half, said Greenberger, who sees "little room for error." She maintains an Underweight rating on Macy's shares and lowered her price target on the stock to $20 from $22 after lowering her 2022 and 2023 gross margin estimates due to expectations for higher e-commerce delivery expenses.
05/16/19
05/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Neutral from Sell at Goldman Sachs with analyst Alexandra Walvis saying she sees a more balanced risk/reward in the wake of the stock's recent underperformance. 2. SAIC (SAIC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Edward Caso saying he has "growing comfort" with the company's ongoing integration of its Engility acquisition and sees the deal producing a "notable improvement" in free cash flow. 3. Scorpio Tankers (STNG) upgraded to Overweight from Neutral at JPMorgan with analyst Noah Parquette saying he's seen a considerable increase in interest from investors in the IMO 2020 product tanker story in recent weeks. 4. KB Home (KBH) and Taylor Morrison (TMHC) were upgraded to Outperform from Sector Perform at RBC Capital. 5. MYR Group (MYRG) upgraded to Buy from Hold at Stifel with analyst Noelle Dilts saying she sees "compelling dynamics" in the electric transmission and distribution market as utilities move investment toward power delivery in order to address reliability concerns, the need for grid hardening, and aging infrastructure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

HAL

Halliburton

$23.76

2.02 (9.29%)

07:48
07/23/19
07/23
07:48
07/23/19
07:48
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 13

    Nov

MARA

Marathon Patent Group

$2.13

-0.08 (-3.62%)

07:48
07/23/19
07/23
07:48
07/23/19
07:48
Hot Stocks
Marathon Patent Group receives Nasdaq acceptance of plan to regain compliance »

Marathon Patent Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$144.97

-0.28 (-0.19%)

, BBBY

Bed Bath & Beyond

$9.35

-0.56 (-5.65%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Recommendations
Wayfair, Bed Bath & Beyond, Macy's analyst commentary  »

Wayfair well positioned…

W

Wayfair

$144.97

-0.28 (-0.19%)

BBBY

Bed Bath & Beyond

$9.35

-0.56 (-5.65%)

M

Macy's

$22.10

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 05

    Aug

IDRA

Idera Pharmaceuticals

$2.54

0.02 (0.79%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Hot Stocks
Idera Pharmaceuticals appoints Elizabeth Tarka as CMO, John Kirby as CFO »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$225.97

1.455 (0.65%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Recommendations
Air Products analyst commentary  »

Air Products price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 22

    Aug

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:45
07/23/19
07/23
07:45
07/23/19
07:45
Hot Stocks
Marinus Pharmaceuticals announces data from Phase 2 Amaryllis study »

The Amaryllis Study…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:44
07/23/19
07/23
07:44
07/23/19
07:44
Hot Stocks
Marinus Pharmaceuticals announces data from Phase 2 Magnolia clinical trial »

Marinus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

07:43
07/23/19
07/23
07:43
07/23/19
07:43
Recommendations
Cadence Design analyst commentary  »

Cadence Design price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$60.62

0.77 (1.29%)

07:43
07/23/19
07/23
07:43
07/23/19
07:43
Recommendations
Itron analyst commentary  »

Canaccord sees several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:41
07/23/19
07/23
07:41
07/23/19
07:41
Hot Stocks
RedHill Biopharma continues to enroll patients in Phase 2a study of YELIVA »

The ongoing Phase 2a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FBP

First BanCorp

$10.74

-0.25 (-2.27%)

07:40
07/23/19
07/23
07:40
07/23/19
07:40
Earnings
First BanCorp reports Q2 EPS 19c, consensus 19c »

Reports Q2 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:40
07/23/19
07/23
07:40
07/23/19
07:40
Hot Stocks
RedHill Biopharma 'working toward' confirmatory Phase 3 study for BEKINDA »

RedHill is currently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

07:40
07/23/19
07/23
07:40
07/23/19
07:40
General news
Treasury Market Outlook: Treasury yields are modestly cheaper »

Treasury Market Outlook:…

ATI

Allegheny Technologies

$25.11

-0.175 (-0.69%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Earnings
Allegheny Technologies reports Q2 ex-items EPS 40c, consensus 34c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Hot Stocks
RedHill Biopharma to initiate Phase 3 study activities with RHB-204 in Q4 »

RedHill plans to initiate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

NOW

ServiceNow

$293.30

3.48 (1.20%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Recommendations
ServiceNow analyst commentary at Needham »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Hot Stocks
RedHill Biopharma says FDA meetings for RHB-104 to take place in 2H198 »

FDA meetings are planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:38
07/23/19
07/23
07:38
07/23/19
07:38
Hot Stocks
RedHill Biopharma plans U.S. launch of Talicia in 4Q19 »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

CR

Crane

$86.50

0.99 (1.16%)

, CIR

Circor

$39.83

1.17 (3.03%)

07:37
07/23/19
07/23
07:37
07/23/19
07:37
Recommendations
Crane, Circor analyst commentary  »

Crane Q2 highlighted by…

CR

Crane

$86.50

0.99 (1.16%)

CIR

Circor

$39.83

1.17 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 01

    Aug

  • 09

    Sep

  • 09

    Sep

RLGY

Realogy

$5.17

-0.08 (-1.52%)

, AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

07:37
07/23/19
07/23
07:37
07/23/19
07:37
Hot Stocks
Realogy launches TurnKey in collaboration with Amazon »

Realogy (RLGY) announced…

RLGY

Realogy

$5.17

-0.08 (-1.52%)

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

AN

AutoNation

$42.01

-0.045 (-0.11%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Recommendations
AutoNation analyst commentary  »

Stephens 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

MYOV

Myovant Sciences

$8.15

-0.25 (-2.98%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Hot Stocks
Myovant Sciences says primary efficacy endpoint met in LIBERTY 2 study »

Myovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Earnings
Kimberly-Clark sees FY19 net sales flat to down 1% y/y, consensus $18.41B »

Prior assumption was down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FB

Facebook

$202.32

3.94 (1.99%)

07:35
07/23/19
07/23
07:35
07/23/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

ARAY

Accuray

$3.91

-0.07 (-1.76%)

07:34
07/23/19
07/23
07:34
07/23/19
07:34
Hot Stocks
CNNC Accuray Medical Technology receives safety license in China »

Accuray provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.